Pentara to Present Rare Disease Power Research at NORD Summit

Pentara will present three posters on rare disease trial statistics at the NORD Breakthrough Summit in Washington, D.C., days after the FDA launched its Rare Disease Framework Initiative. The research focuses on ways to recover statistical power in small trials, a core issue for getting evidence that can support treatment decisions in rare diseases.

Why it matters: - Small rare disease trials often lack the patient numbers needed to show treatment effects with standard statistical methods. - Pentara’s research is aimed at helping sponsors generate stronger evidence from limited populations. - The timing matters because the work lands just after the FDA launched its Rare Disease Framework Initiative, which is meant to align regulatory expectations with the evidence small patient populations can realistically produce.

What happened: - Pentara Corporation will present research at the NORD® Rare Diseases & Orphan Products Breakthrough Summit® in Washington, D.C., from October 25–27. - Founder and CEO Suzanne Hendrix, PhD, and Senior Vice President, Statistics Sam Dickson will present three posters. - The presentation comes days after the U.S. Food and Drug Administration announced its Rare Disease Framework Initiative.

The details: - The first poster, “The 100-to-1 Imbalance: Recovering Statistical Power in Rare Disease Trials Through Global Statistical Tests (GSTs),” examines how combining multiple endpoints into one pre-specified test can recover statistical power in small trials. - The second poster, “Optimizing Power and Sample Size for Biomarker-Driven Basket Trials in Neurodegenerative Diseases,” evaluates how one biomarker-driven protocol can test several indications, reduce total enrollment and help sponsors choose which indication advances to Phase 3. - The third poster, “Statistical Considerations for Assessing Rare Events in Single-Arm Studies,” lays out conservative assumptions needed in single-arm studies and shows how low, well-defined background response rates can let smaller cohorts detect modest treatment effects. - Pentara describes itself as an independent biostatistics and regulatory consulting firm based in Salt Lake City, Utah. - Pentara says its work focuses on measuring change in slow, heterogeneous, hard-to-measure diseases, especially neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease, ALS and frontotemporal dementia, as well as rare disease. - Pentara also says its statisticians develop composite endpoints and novel analytic methods, including Global Statistical Tests, to detect treatment effects in small and variable patient populations.

Between the lines: - The FDA’s new framework effort and Pentara’s poster topics point to the same problem: rare disease evidence is often sparse, and trial design has to do more with less. - Hendrix argues that conventional trial designs can protect against approving ineffective treatments more than they protect against rejecting effective ones, especially in small populations. - Hendrix said Global Statistical Tests should be part of the FDA’s framework from the start because they combine endpoints into a single pre-specified test that reflects the total biology of the disease.

What's next: - Summit attendees can meet the Pentara team at the poster sessions during the event. - Copies of the posters will be available on request after the summit at Pentara contact page. - Pentara says more information is available at pentara.com.

The bottom line: - Pentara is using the NORD summit to make the case that rare disease trials need statistical tools designed for tiny patient populations, not adapted after the fact.